Condition
ADME
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (3)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07083817Phase 1CompletedPrimary
Mass Balance Study of [14C]Xeruborbactam (QPX7728) in Healthy Adult Male Participants
NCT03525405Phase 1CompletedPrimary
A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects
NCT05023811Phase 1Completed
A Study of the ADME of [14C]RIST4721 in Healthy Male Subjects
NCT01969994Not ApplicableCompletedPrimary
Absorption, Metabolism, and Excretion of (-)-[2-14C]Epicatechin in Humans
Showing all 4 trials